This course includes the recording of a live Instructional Course from the 2026 AOSSM Annual Meeting.
Please Note: The Q&A QR code in the Recording is currently inactive. Any questions submitted through it will not be monitored or answered.
IC03- Hip Pain: What to do When It's Not the Labrum?
Course Description:
Muscle and soft tissue injuries around the hip and pelvis are among the most common and challenging conditions encountered in athletes, requiring accurate diagnosis and evidence-based management to optimize recovery and return to play. This session will review the evaluation and treatment of key sports-related injuries, including hip subluxation versus dislocation, rectus femoris injuries, hamstring injuries, physeal injuries in the growing athlete, and athletic pubalgia. Faculty will discuss current treatment strategies, rehabilitation considerations, and return-to-sport decision-making while highlighting practical approaches for caring for athletes across all levels of competition. An interactive question-and-answer discussion will conclude the session, allowing participants to apply concepts to real-world clinical scenarios.
Learning Objectives:
By the end of this course, participants should be able to:
- At the conclusion of this session, participants will be able to apply evidence-based evaluation and management strategies to accurately diagnose and treat muscle and soft tissue injuries of the hip and pelvis, including hip instability, rectus femoris injuries, hamstring injuries, physeal injuries, and athletic pubalgia, to optimize return-to-sport outcomes.
Faculty:
- James Ross, MD
- Christopher M. Larson, MD
- Asheesh Bedi, MD, PhD
- Joshua Harris, MD
- Alexzander E. Poor, MD
- Jeffrey J. Nepple, MD
ACCREDITATION STATEMENT The American Orthopaedic Society for Sports Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
|
|
ABOS MOC CREDIT STATEMENT: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Orthopaedic Surgery’s (ABOS) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABOS credit.
AMA CREDIT DESIGNATION STATEMENT The American Orthopaedic Society for Sports Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CLAIMING CREDIT In order to obtain AMA PRA Category 1 Credit™ participants must complete the activity and online evaluation. No hard copy submissions will be accepted.
American Orthopaedic Society for Sports Medicine (AOSSM) (BOC AP# P460) is approved by the Board of Certification, Inc. to provide continuing education to Athletic Trainers. This program is eligible for a maximum of 1 Category A CEUs. ATs should claim only those hours actually spent in the educational program.
|
| |
James Ross, MD
"has no relevant financial relationship(s) with ineligible companies to disclose"
Christopher Larson, MD
Responsive Arthroscopy: Consultant (Ongoing)|Responsive Arthroscopy: Own stock options in a privately held ineligible company (Ongoing)|Smith & Nephew: Consultant (Ongoing)
Asheesh Bedi, MD
Arthrex Inc: Consultant (Ongoing)|Arthrex Inc: Royalties (Ongoing)
Joshua Harris, MD
SLACK, Inc.: Royalties (Ongoing)|Smith & Nephew: Consultant (Ongoing)|Thieme, Inc: Royalties (Ongoing)
Jeff Nepple, MD, MS
Smith and Nephew: Consultant (Ongoing)|Smith and Nephew: Researcher (Ongoing)|Smith and Nephew: Speaker (Ongoing)|Stryker: Researcher (Ongoing)|Zimmer Biomet: Researcher (Ongoing)
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, we have implemented measures to identify and mitigate relevant financial relationships. All individuals in control of content have disclosed their financial relationships with ineligible companies within the past 24 months. These relationships have been reviewed and mitigated.
ORIGINAL RELEASE DATE: 8/1/2026
EXPIRATION DATE: 7/31/2029